Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests;La prevención primaria con aspirina de enfermedades cardiovasculares en personas diabéticas. Revisión de las pruebas disponibles

Revista Espanola de Salud Publica

Volumn 80, Issue 6, 2006, Pages 613-620

  Bobes, Carmen Maciá ^a,d   Fernández, Aránzazu Ronzón ^b   García, Elisa Fernádez ^c  

^a HOSPITAL SAN AGUSTÍN   (Spain)

^b Medicina de Familia Avilés   (Spain)

^c Medicina de Familia   (Spain)

^d NONE   (Spain)

Author keywords

Aspirin; Cardiovascular diseases; Diabetes mellitus, type 1; Diabetes mellitus, type 2; Guidelines; Primary prevention; Review literature; Societies, scientific

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; PRIMARY PREVENTION; REVIEW; RISK FACTOR;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK FACTORS;

EID: 33847020103     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación española de la Guía europea de prevención cardiovascular. Rev Esp Salud Pública 2004;78:435-8.
2. Grupo para el Estudio de la Diabetes en Atención Primaria (Gedaps), Sociedad Española de Cardiologĩa (SEC), Sociedad Española de Diabetes (SED), Sociedad Española de Medicina Interna (SEMI). Documento 2005 de consenso entre varias sociedades científicas sobre pautas de manejo del paciente tipo 2 en España. Abordaje de otros factores de riesgo cardiovascular. Av Diabetol 2005;21 Supl 1:34-44.
3. Tercer grupo de trabajo de las Sociedades Europeas y otras Sociedades sobre Prevención Cardiovascular en la Práctica Clínica. Guía europea de prevención cardiovascular en la práctica clínica. Rev Esp Salud Pública 2004;78:439-56.
4. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234-64.
5. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
6. Pearson TA, Blair SN, Daniels SR, et al, American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91.
7. American Diabetes Association. Standards of medical care. Diabetes Care 2006;29 Supl 1:4-42.
8. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004;27 Supl 1:72-3.
9. US Preventive Services Task Force Ratings: Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services. [Internet] Third Edition: Periodic Updates, 2000-2003. Rockville : Agency for Healthcare Research and Quality. [citado el 18 de junio de 2006]. Disponible en: http://www.ahrq.gov/clinic/3rduspstf/ratings.htm
10. Steering Committee for the Physicianś Health Study Research Group. Final report on the aspirin component of the ongoing Physicianś Health Study. N Engl J Med 1989;321:129-35.
11. The ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292-300.
12. Hansson L, Zanchetti A, Carruthers SG, et al, HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
15. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown D. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295:306-13.
16. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
17. Medical Research Council. Thrombosis Prevention Trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351:233-41.
18. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89-95.
19. Sacco M, Pellegrini F, Roncaglioni MC, et al, The PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-72.
20. Colwell JA. Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes Care 2003;26:3349-50.
21. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004;113:97-9.
22. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99-103.
23. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 2006;97:567-70.
24. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
25. Levin RI. The puzzle of aspirin and sex. N Engl J Med 2005;352:1366-8.
26. Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: Semantic complexity and aspirin resistance. Circulation 2004;110;1706-8.
27. Botas Cervero P, Delgado Álvarez E, Castaño Fernández G, Díaz de Greñu C, Prieto Santiago J, Díaz Cadórniga FJ. Prevalencia de diabetes mellitus e intolerancia a la glucosa en población entre 30 y 75 años en Asturias, España. Rev Clin Esp 2002;202:421-9.
28. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An update on the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.